AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06509607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric Lower Limb Training Program
Description: A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
Study NCT06509607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Lower Limb Training Program
Description: A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
Study NCT06522919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell (DC) Vaccine
Description: Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
Study NCT06201559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole IP 400 mg
Description: Albendazole IP 400 mg tablets will be administered under fed conditions
Study NCT06201559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Description: Albendazole 400 mg tablets will be administered under fed conditions
Study NCT04040296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Action Team Recommendations
Description: Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
Study NCT05756088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure the levels of dd-cf DNA
Description: Blood draw to measure the levels of dd-cf DNA.
Study NCT05305833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: ATMP
Study NCT05049213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray and 1% PVP- mouthwash and gargle
Description: Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time
Study NCT06041503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
Study NCT06041503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
Study NCT06507748 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AlgometRx Nociometer
Description: Novel objective pain measurement device
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04791748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular tests
Description: Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04791748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04791748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
Study NCT05256225 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose-Rate Vaginal Cuff Brachytherapy
Description: Undergo vaginal brachytherapy
Study NCT05188079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: high nitrate supplement
Study NCT05256225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Vaginal Cuff Brachytherapy
Description: Undergo vaginal brachytherapy
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Description: Given SC
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05256225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05188079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: placebo
Study NCT06174805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Description: Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
Study NCT06274034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06274034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear MUSE S headband
Study NCT06274034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Participate in meditation
Study NCT06274034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05256225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05256225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05256225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab/Hyaluronidase-oysk
Description: Given SC
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or CT/MRI
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or CT/MRI
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT
Study NCT06325046 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Adaptive Radiation Therapy
Description: Undergo near margin-less ART
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04858334 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI
Study NCT04858334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04858334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05652478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide
Description: 25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.
Study NCT05652478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: 50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
Study NCT04569591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthrel
Description: Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
Study NCT06555562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Stimulation
Description: Ultrasound therapy will be administered to the appropriate target.
Study NCT06555562 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active ultrasound stimulation
Description: Non-active ultrasound therapy will be administered to the appropriate target
Study NCT05652465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)
Description: Device described in protocol
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06325046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy
Description: Undergo standard SABR
Study NCT06325046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06325046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05418504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: Dental anesthesia, used to do any dental procedure
Study NCT05694871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04269902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04269902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV
Study NCT04269902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT04269902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04269902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04269902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04269902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04269902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO
Study NCT04269902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05694871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT05694871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study NCT02588807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirit1
Description: Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
Study NCT05675410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05675410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05675410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin Sulfate
Description: Given IV
Study NCT05675410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV
Study NCT05675410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT05675410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET-CT
Study NCT05675410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET-CT
Study NCT04734418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
Study NCT04734418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
Study NCT05128513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DELP
Description: The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
Study NCT04691141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
Study NCT04851119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04851119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan
Study NCT04851119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV
Study NCT04851119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study NCT06517251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm-hand BOOST
Description: Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation.
Study NCT06517251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb BOOST
Description: L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
Study NCT05675410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05666492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet-rich plasma will be placed on the olfactory epithelium topically.
Study NCT05666492 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be placed on the olfactory epithelium topically.
Study NCT04677374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
Study NCT04677374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Health Education
Description: More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
Study NCT04677374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS/telephonic Tracing
Description: SMS tracing to remind participants of VMMC appointments
Study NCT04677374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation Reimbursement
Description: Transportation reimbursement to offset the cost of transportation for VMMC appointments
Study NCT04998474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FRAME-001 personalized vaccine
Description: Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
Study NCT05675410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Given IV
Study NCT05675410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV